Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Quality of life (QOL) assessment of MIP (mitomycin, ifosfamide and cisplatin) chemotherapy in advanced non-small cell lung cancers (NSCLC)
Autore:
Han, JY; Kim, HK; Choi, BG; Moon, H; Hong, YS; Lee, KS;
Indirizzi:
Catholicreaiv Korea, Ctr Canc, Coll Med, Dept Internal Med, Seoul, South Ko Catholic Univ Korea Seoul South Korea ept Internal Med, Seoul, South Ko
Titolo Testata:
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
fascicolo: 12, volume: 28, anno: 1998,
pagine: 749 - 753
SICI:
0368-2811(199812)28:12<749:QOL(AO>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
ADVANCED BREAST-CANCER; VALIDATION; THERAPY; TRIALS;
Keywords:
non-small cell lung cancer; quality of life; MIP treatment; LASA scales;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Han, JY CatholicGu,iv Korea, St Pauls Hosp, Coll Med, Dept Internal Med,Dongdaemun Catholic Univ Korea 620-56 Jeonnong Dong Seoul South Korea 130022
Citazione:
J.Y. Han et al., "Quality of life (QOL) assessment of MIP (mitomycin, ifosfamide and cisplatin) chemotherapy in advanced non-small cell lung cancers (NSCLC)", JPN J CLIN, 28(12), 1998, pp. 749-753

Abstract

Background: Quality of life (QOL) assessment has emerged to measure and quantify the balance between treatment benefit and toxicity, and has a value in predicting response and overall survival in cancer patients. Methods: From July 1995 to February 1997, 38 symptomatic patients with advanced non-small cell lung cancer (NSCLC) were treated with MIP chemotherapy(mitomycin 6 mg/m(2), ifosfamide 3000 mg/m(2) and cisplatin 50 mg/m(2) on day 1 every 3 weeks). Patients were assessed for QOL including physical well-being, general symptoms and lung cancer-specific symptoms, as well as objective response. Results: The overall response rate was 38.9% (14/36, all were partial response) and the median duration of response was 3.5 months [95% confidence interval (CI) 2.0-4.0]. The median duration of overall survival was 7 months (95% CI 5.9-8.5). The overall improvement of QOL was 58.3% with 21 patientsfeeling better on treatment. The toxicity of chemotherapy was mild, mainlynausea/vomiting and minimal alopecia. Using multiple clinical predictors of survival (age, histology, stage, performance status), only change of QOL emerged significantly (P = 0.0007). Conclusions: MIP had an endurable response and low toxicity profile, and provided good QOL. Integral QOL data in our study provided the strong prediction of survival in advanced NSCLC. Further experienced QOL study will provide greatly enhanced outcome data in clinical trials.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 12:55:31